Tubulin inhibitor 12 (Hit 9) is a recently developed compound with potent tubulin inhibitory effects (IC50 = 25.3 μM) and significant anti-tumor and anti-proliferative activities, making it a promising candidate for cancer treatment [1].

Tubulin inhibitor 12, when administered in concentrations ranging from 0-100 μM for 72 hours, demonstrates moderate and broad-spectrum anti-proliferative effects, as observed in a Cell Proliferation Assay conducted on HepG2, A549, and HCT116 cell lines. Specifically, it exhibited IC50 values of 49.13 μM for HepG2, 52.84 μM for A549, and 70.10 μM for HCT116 cells.